Ginkgo Bioworks Holdings (DNA)
Healthcare
Biotechnology
8.10 $
+0.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Ginkgo Bioworks Holdings (DNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -46 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -74 | -74 | -58 | -89 | -84 | -104 | -42 | -52 | -40 | -32 | -48 | -46 | -166 | |
| 26 | 21 | 13 | 13 | 17 | 17 | 16 | 15 | 16 | 14 | 14 | 13 | 56 | |
| 61 | 53 | 43 | 41 | 37 | 14 | 21 | 20 | 22 | 18 | 21 | 16 | 77 | |
| 93 | 211 | – | – | – | – | – | – | – | – | – | – | – | |
| -12 | -1.8 | 42 | 0.3 | 5.9 | -98 | 2.2 | -12 | -23 | 14 | -24 | -14 | -47 | |
| 14 | 4.4 | 3.4 | 6.7 | 27 | 15 | 14 | 7.6 | 0.0 | 7.7 | 15 | 1.9 | 25 | |
| -11 | -3.4 | -47 | -12 | -27 | -10 | -13 | -199 | -64 | -73 | 95 | 23 | -18 | |
| 0.6 | – | 0.6 | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | – | 0.0 | – | – | 0.1 | 0.1 | 0.0 | 0.0 | 10 | 19 | – | – | |
| -0.3 | -0.3 | – | – | – | -0.2 | -0.2 | -0.2 | -0.1 | 0.0 | 0.0 | 0.0 | -0.2 | |
| -1.4 | -0.3 | -0.6 | -0.8 | -0.2 | -0.5 | -0.2 | -0.2 | -0.1 | 9.9 | 8.1 | 0.0 | 18 | |
| -86 | -77 | -104 | -105 | -111 | -114 | -56 | -250 | -106 | -94 | 54 | -23 | -169 | |
| -87 | -78 | -61 | -96 | -111 | -119 | -56 | -59 | -40 | -32 | -63 | -48 | -183 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.